FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994121001> ?p ?o ?g. }

• W1994121001 endingPage "387" @default.
• W1994121001 startingPage "380" @default.
• W1994121001 abstract "It is unclear how hepatic glucocorticoid receptor (GR) function and hypothalamic-pituitary-adrenal axis tone contribute to the diabetic state and in particular whole-body glucose fluxes. We have previously demonstrated that long-term exposure to hepatic GR inhibition lowers glucose levels in ob/ob mice (J Pharmacol Exp Ther 2005;314:191). The purpose of this study was to determine the effects of a novel GR antagonist (A-348441) on whole-body glucose fluxes in a model of insulin resistance, the Zucker fatty (fa/fa) rat. After an overnight fast, euglycemic-hyperinsulinemic clamp studies were performed 2 hours after single oral dosing as follows: (1) A-348441 at 100 mg/kg or (2) vehicle. Furthermore, effects of 1 week of treatment with either vehicle or A-348441 (3, 10, 30, or 100 mg/kg PO, once per day) were investigated in separate groups of rats fasted overnight and given a final dose of their respective compound, followed 2 hours later by a euglycemic-hyperinsulinemic clamp. One week after catheter implantation, body weight returned to presurgery levels, with no difference between groups. A single, 100-mg/kg dose of A-348441 significantly increased glucose infusion rate 4-fold (P < .05) and reduced endogenous glucose production by 37% (P < .05) but did not change glucose disposal. After 1 week of sub-long-term dosing, fasting glucose levels were reduced dose-dependently with A-348441 vs vehicle (-8%, not significant; -14%, -20%, and -25%, P < .05, at 3, 10, 30, and 100 mg/kg, respectively) with no observed hypoglycemia or change in fasting insulin levels. A-348441 increased the glucose infusion rates after 1-week treatment by 1.3-, 5.7-, 7.3-, and 6.4-fold (P < .05). Endogenous glucose production was decreased (-25%, -44%, -50%, and -61%, P < .05), whereas glucose disposal was increased (29% and 13%, not significant; 23% and 34%, P < .05), with A-348441. In summary, single-dose treatment with the liver-selective GR antagonist A-348441 decreases glucose production with no effect on glucose disposal or fasting glucose levels. After 1 week of treatment with A-348441, (1) there was no effect on body weight, (2) fasting glucose levels decreased, (3) both glucose disposal and glucose infusion rate increased during clamping, and (4) endogenous glucose production was greatly reduced. In addition, hepatic glucose production was highly correlated with fasting glucose levels (r = 0.97). In conclusion, these results indicate that A-348441 increases insulin sensitivity at both the liver and peripheral tissues, leading toward a normalization of the insulin resistant state. Furthermore, with 1-week vs single-dose liver-selective glucocorticoid antagonism, we have determined that the peripheral effect is secondary to the primary event of reduced hepatic glucose production. The approach of inhibiting the hepatic GR may be an advantageous treatment paradigm for individuals with type 2 diabetes mellitus." @default.
• W1994121001 created "2016-06-24" @default.
• W1994121001 creator A5002953134 @default.
• W1994121001 creator A5007388418 @default.
• W1994121001 creator A5017259712 @default.
• W1994121001 creator A5017859552 @default.
• W1994121001 creator A5063405239 @default.
• W1994121001 creator A5065114279 @default.
• W1994121001 creator A5067627069 @default.
• W1994121001 creator A5077385501 @default.
• W1994121001 date "2007-03-01" @default.
• W1994121001 modified "2023-10-01" @default.
• W1994121001 title "Liver-selective glucocorticoid receptor antagonism decreases glucose production and increases glucose disposal, ameliorating insulin resistance" @default.
• W1994121001 cites W1937194455 @default.
• W1994121001 cites W1967716436 @default.
• W1994121001 cites W1982538739 @default.
• W1994121001 cites W2039556928 @default.
• W1994121001 cites W2040050338 @default.
• W1994121001 cites W2054863769 @default.
• W1994121001 cites W2055645626 @default.
• W1994121001 cites W2058592642 @default.
• W1994121001 cites W2095590290 @default.
• W1994121001 cites W2096329362 @default.
• W1994121001 cites W2119186903 @default.
• W1994121001 cites W2133208346 @default.
• W1994121001 cites W2158062274 @default.
• W1994121001 cites W2203608723 @default.
• W1994121001 cites W2333204497 @default.
• W1994121001 cites W2338145542 @default.
• W1994121001 cites W4230138330 @default.
• W1994121001 cites W4231664412 @default.
• W1994121001 cites W4232580539 @default.
• W1994121001 cites W4241387399 @default.
• W1994121001 cites W4250236863 @default.
• W1994121001 cites W4254695749 @default.
• W1994121001 doi "https://doi.org/10.1016/j.metabol.2006.10.021" @default.
• W1994121001 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17292727" @default.
• W1994121001 hasPublicationYear "2007" @default.
• W1994121001 type Work @default.
• W1994121001 sameAs 1994121001 @default.
• W1994121001 citedByCount "38" @default.
• W1994121001 countsByYear W19941210012013 @default.
• W1994121001 countsByYear W19941210012015 @default.
• W1994121001 countsByYear W19941210012016 @default.
• W1994121001 countsByYear W19941210012017 @default.
• W1994121001 countsByYear W19941210012018 @default.
• W1994121001 countsByYear W19941210012019 @default.
• W1994121001 countsByYear W19941210012020 @default.
• W1994121001 countsByYear W19941210012021 @default.
• W1994121001 countsByYear W19941210012022 @default.
• W1994121001 countsByYear W19941210012023 @default.
• W1994121001 crossrefType "journal-article" @default.
• W1994121001 hasAuthorship W1994121001A5002953134 @default.
• W1994121001 hasAuthorship W1994121001A5007388418 @default.
• W1994121001 hasAuthorship W1994121001A5017259712 @default.
• W1994121001 hasAuthorship W1994121001A5017859552 @default.
• W1994121001 hasAuthorship W1994121001A5063405239 @default.
• W1994121001 hasAuthorship W1994121001A5065114279 @default.
• W1994121001 hasAuthorship W1994121001A5067627069 @default.
• W1994121001 hasAuthorship W1994121001A5077385501 @default.
• W1994121001 hasConcept C126322002 @default.
• W1994121001 hasConcept C134018914 @default.
• W1994121001 hasConcept C170493617 @default.
• W1994121001 hasConcept C17093226 @default.
• W1994121001 hasConcept C185592680 @default.
• W1994121001 hasConcept C2776885963 @default.
• W1994121001 hasConcept C2777391703 @default.
• W1994121001 hasConcept C2777866211 @default.
• W1994121001 hasConcept C2778808658 @default.
• W1994121001 hasConcept C2779306644 @default.
• W1994121001 hasConcept C2780352109 @default.
• W1994121001 hasConcept C2780841215 @default.
• W1994121001 hasConcept C3018667095 @default.
• W1994121001 hasConcept C59493245 @default.
• W1994121001 hasConcept C71924100 @default.
• W1994121001 hasConceptScore W1994121001C126322002 @default.
• W1994121001 hasConceptScore W1994121001C134018914 @default.
• W1994121001 hasConceptScore W1994121001C170493617 @default.
• W1994121001 hasConceptScore W1994121001C17093226 @default.
• W1994121001 hasConceptScore W1994121001C185592680 @default.
• W1994121001 hasConceptScore W1994121001C2776885963 @default.
• W1994121001 hasConceptScore W1994121001C2777391703 @default.
• W1994121001 hasConceptScore W1994121001C2777866211 @default.
• W1994121001 hasConceptScore W1994121001C2778808658 @default.
• W1994121001 hasConceptScore W1994121001C2779306644 @default.
• W1994121001 hasConceptScore W1994121001C2780352109 @default.
• W1994121001 hasConceptScore W1994121001C2780841215 @default.
• W1994121001 hasConceptScore W1994121001C3018667095 @default.
• W1994121001 hasConceptScore W1994121001C59493245 @default.
• W1994121001 hasConceptScore W1994121001C71924100 @default.
• W1994121001 hasIssue "3" @default.
• W1994121001 hasLocation W19941210011 @default.
• W1994121001 hasLocation W19941210012 @default.
• W1994121001 hasOpenAccess W1994121001 @default.
• W1994121001 hasPrimaryLocation W19941210011 @default.
• W1994121001 hasRelatedWork W2002175422 @default.
• W1994121001 hasRelatedWork W2012273189 @default.
• W1994121001 hasRelatedWork W2026316039 @default.

• next